Johnson & Johnson

01/08/2025 | Press release | Distributed by Public on 01/08/2025 07:04

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease